P/E ratio for Cardiovascular Systems (CSII)
P/E ratio as of October 2023 (TTM): -20.6
According to Cardiovascular Systems's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -20.6186. At the end of 2021 the company had a P/E ratio of -25.4.
P/E ratio history for Cardiovascular Systems from 2006 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -25.4 | -67.44% |
| 2020 | -77.9 | -66.31% |
| 2019 | -231 | -132.49% |
| 2018 | 712 | -400.65% |
| 2017 | -237 | 751.31% |
| 2016 | -27.8 | 174.23% |
| 2015 | -10.1 | -64.24% |
| 2014 | -28.4 | -2.35% |
| 2013 | -29.1 | 133.86% |
| 2012 | -12.4 | -5.39% |
| 2011 | -13.1 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 31.2 | -251.34% | 🇺🇸 USA |
 Medtronic MDT | 28.6 | -238.67% | 🇮🇪 Ireland |
 Boston Scientific BSX | 88.0 | -526.88% | 🇺🇸 USA |
 Merit Medical MMSI | 43.1 | -309.02% | 🇺🇸 USA |
 LeMaitre Vascular LMAT | 48.4 | -334.67% | 🇺🇸 USA |
 AngioDynamics ANGO | -5.64 | -72.66% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.